2nd Generation Antigen Presenting Cells for Multiple KRAS Mutations
Time: 9:25 am
day: Day Two
Details:
- SQZ APC mechanism overcomes challenges of previous cancer vaccines with CD8 T-cell activation and can be enhanced with mRNA cargo combinations
- SQZ APC clinical program overview: Safety and manufacturability of SQZ’s APC candidate in solid tumors
- Preclinical data for SQZ’s enhanced APC platform in targeting KRAS G12D and G12V mutation
